<DOC>
	<DOCNO>NCT01452113</DOCNO>
	<brief_summary>The purpose study compare effect single administration DPP-IV inhibitor ( vildagliptin : Galvus ® ) versus treatment two population diabetic patient : without diabetic autonomic neuropathy ( NA , i.e . control group ) diabetic autonomic neuropathy ( i.e . neuropathy group ) . The investigator hypothesize therapeutic efficacy DPP-IV inhibitor partly mediate autonomic nervous system . This hypothesis validate low glycemic response DPP-IV inhibitor treatment observe neuropathy group compare control .</brief_summary>
	<brief_title>Effect Autonomic Neuropathy Efficacy DPP-IV Inhibitor ( Galvus ) Therapy</brief_title>
	<detailed_description>Recently publish work demonstrated animal control pancreatic hormone secretion due , least part , action GLP-1 via autonomic nervous system . Therefore , rhe investigator hypothesize altered autonomic nervous system could explain , least part , alter therapeutic efficacy DPP-IV inhibitor observe patient . Our aim validate concept human . The objective physiopathological , monocentric , comparative , open , parallel study compare effect single administration DPP-IV ( vildagliptin : Galvus ® ) two population type 1 diabetic patient : control group 12 patient without diabetic autonomic neuropathy ( NA ) group 12 patient NA . This proof concept study enrol type 1 diabetic patient avoid confound factor related endogen insulin secretion frequent polymedication type 2 diabetic patient . The response evaluate patient relative difference pre-and post-glucagon concentration follow test meal , measure absence presence treatment DPP4 inhibitor . Expected result : DPP-4 inhibitor lead reduction 20 30 % glucagon level patient without NA small decrease patient NA .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<criteria>type 1 diabetes mellitus multiple daily insulin injection therapy continuous insulin infusion ( insulin pomp ) therapy recent ( &lt; 1 year ) write diagnosis autonomic neuropathy available ewing score &gt; 2 patient include `` neuropathy '' group ewing score &lt; = 0.5 patient include ' '' control '' group HbA1C &lt; = 10 % screen visit stable ( +/ 1 % ) autonomous neuropathy diagnosis inclusion visit severe chronic renal insufficiency define estimate GFR &lt; 30 ml/min calculate MDRD formula ) proliferative retinopathy need panphotocoagulation hepatic enzyme ( ALAT , ASAT ) great 3 time upper limit congestive heart failure NYHA functional class IIIIV clinical sign gastroparesis ongoing gastric empty therapy history bariatric surgery galvus therapy contra indication : know allergy hypersensitivity princeps excipients , galactose intolerance , lapp lactase deficiency , glucose galactose malabsorption ongoing systemic corticoid therapy metformin therapy day study visit haemoglobin alteration pregnancy pregnancy willing lactation ongoing clinical study participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>DPP-IV protein</keyword>
	<keyword>Glucagon-Like Peptide 1</keyword>
	<keyword>autonomic neuropathy</keyword>
</DOC>